Browse
Submit Data
Databases
API
Help

Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RNA-seq of in vitro radio-resistant human GBM cell line (LN229) and patient-derived culture (PS1) post YBX3 knockdown

ABSTRACT: Glioblastoma (GBM)is the most aggressive brain tumor with poor overall survival due to high recurrence rate. The recurrent GBM tumors are highly aggressive and resistant to therapy. In the current study, we explored the potential role of Y-box binding protein 3 (YBX3) in glioblastoma aggressiveness. We found significantly high expression of YBX3 in GBM compared to low-grade glioma, and the expression of YBX3 significantly correlated with poor overall and disease-free survival of GBM patients. Knockdown of YBX3 in established GBM primary cultures and cell line abrogated the invasion and migration of GBM cells in vitro, and tumorigenicity and metastasis in vivo. Further, we found high expression of YBX3 in the recurrent GBM patient biopsies. To decipher the genes and biological pathways by which YBX3 regulates the GBM aggressiveness, we performed RNA-Seq experiment on LN229-Relapse and patient-derived primary culture relapse cells (PS1) after stable knockdown of YBX3.

INSTRUMENT(S): Illumina NovaSeq 6000

ORGANISM(S): Homo sapiens

SUBMITTER: Shilpee Dutt

PROVIDER: E-MTAB-14224 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

ACCESS DATA

Json Xml

Similar Datasets

RNA-seq for siPRKDC and siControl in human HL-60/MX2 mitoxantrone resistant derivative of the HL-60 cell line

Project description:Anthracyclines, topoisomerase 2 enzyme poison that results in DNA damage, are currently used in acute myeloid leukemia (AML) treatment. Identifying the mechanisms underlying drug resistance remains an important question. Here, using a mitoxantrone-resistant cell line (HL-60/MX2), we found upregulation of DNA-PKcs, independent of the DNA damage response. We demonstrated that anthracyclines failed to induce DNA damage in resistant cells owing to the loss of expression of their target enzyme-TOP2B, rendered by DNA-PKcs directly binding to its promoter upstream region as a transcription repressor. Importantly, DNA-PKcs kinase activity inhibition re-sensitized AML relapse primary cultures and cells resistant to mitoxantrone and abrogated their tumorigenic potential in a xenograft mouse model. However, to explore other putative dysregulated pathways and genes, we performed RNA-seq experiments on HL-60/MX2 cells after siRNA-mediated knockdown of PRKDC.

2025-12-31 | E-MTAB-13769 | biostudies-arrayexpress

Transcriptome analysis of AML samples at diagnosis and relapse after Hematopoietic Stem Cell Transplantation (HSCT)

Project description:Transcriptome profiling of Acute Myeloid Leukemia samples. This dataset includes patients with diagnosis of de novo or secondary AML who experienced non-HLA loss disease relapse after allo-HCT, and for whom paired pre- and post-transplant viable leukemic samples were available.

2019-01-29 | E-MTAB-7456 | biostudies-arrayexpress

miRNA profiles in Primary and Recurrent GBM

Project description:Glioblastoma (GBM) bears a dismal prognosis with rapid relapse following complete resection and radiochemotherapy. The involvement of microRNAs in tumor progression has been demonstrated in hepatoma, breast cancer, and prostate cancers. However, the microRNAs involved in modulating the progression and relapse of GBM are still unclear. Initially, we compared the miRNA expression profiles between primary and recurrent GBM tissues from the same patient in twelve independent cases. miRNA expression profiles between primary and recurrent GBM tissues from the same patient in twelve independent cases.

2014-09-28 | E-GEOD-32466 | biostudies-arrayexpress

miRNA profiles in Primary and Recurrent GBM

2014-09-28 | GSE32466 | GEO

Patient specific orthotopic glioblastoma xenograft models recapitulate the histopathology and biology of human glioblastomas in situ (gene expression)

Project description:Frequent discrepancies between preclinical and clinical results of anti-cancer agents demand a reliable translational platform that can precisely recapitulate the biology of human cancers. Another critical unmet need is the ability to predict therapeutic responses for individual patients. Toward this goal, we have established a library of orthotopic glioblastoma (GBM) xenograft models using surgical samples of GBM patients. These patient-specific GBM xenograft tumors recapitulate histopathological properties and maintain genomic characteristics of parental GBMs in situ. Furthermore, in vivo irradiation, chemotherapy, and targeted therapy of these xenograft tumors mimic the treatment response of parental GBMs. We also found that establishment of orthotopic xenograft models portends poor prognosis of GBM patients and identified the gene signatures and pathways signatures associated with the clinical aggressiveness of GBMs. Together, the patient-specific orthotopic GBM xenograft library represent the preclinically and clinically valuable “patient tumor’s phenocopy” that represents molecular and functional heterogeneity of GBMs. Gene expression profiling experiments were conducted for 58 human glioblastoma samples using Affymetrix Human Gene 1.0 ST arrays according to manufacturer's protocol.

2013-01-18 | E-GEOD-42669 | biostudies-arrayexpress

LSD1-directed therapy affects glioblastoma tumorigenicity by deregulating the protective ATF4-dependent integrated stress response

Project description:Despite the progress in medicine, no significant advancement in the standard of care for glioblastoma (GBM) patients have been reached. GBM heterogeneity, poor blood–brain barrier penetration and resistance to therapy highlight the need for new targets and clinical treatments. A step toward clinical translation includes the eradication of GBM Tumor-Initiating Cells (TICs), responsible for GBM heterogeneity and relapse. By using patient-derived TICs and xenograft orthotopic models, we demonstrate that Lysine-specific histone demethylase 1A (LSD1) is a druggable target in GBM. Here, we analyze the effect of LSD1i treatment on histone H3K4 in primary human cells and mouse brains.

2022-04-14 | PXD025781 | Pride

Histone modification and TF ChIP-Seq for glioblastoma cell lines and neural stem cells

Project description:Glioblastoma (GBM) is thought to be driven by a sub-population of cancer stem cells (CSCs) that self-renew and recapitulate tumor heterogeneity, yet remain poorly understood. Here we present a comparative epigenomic analysis of GBM CSCs that reveals widespread activation of genes normally held in check by Polycomb repressors. These activated targets include a large set of developmental transcription factors (TFs) whose coordinated activation is unique to the CSCs. We demonstrate that a critical factor in the set, ASCL1, activates Wnt signaling by repressing the negative regulator DKK1. We show that ASCL1 is essential for maintenance and in vivo tumorigenicity of GBM CSCs. Genomewide binding profiles for ASCL1 and the Wnt effector LEF1 provide mechanistic insight and suggest widespread interactions between the TF module and the signaling pathway. Our findings demonstrate regulatory connections between ASCL1, Wnt signaling and collaborating TFs that are essential for the maintenance and tumorigenicity of GBM CSCs. Histone modification profiling for multiple marks by ChIP-Seq in untreated glioblastoma cancer stem cells, glioblastoma non-stem cells and neural stem cells

2013-05-28 | E-GEOD-46014 | biostudies-arrayexpress

Patient specific orthotopic glioblastoma xenograft models recapitulate the histopathology and biology of human glioblastomas in situ (CGH)

Project description:Frequent discrepancies between preclinical and clinical results of anti-cancer agents demand a reliable translational platform that can precisely recapitulate the biology of human cancers. Another critical unmet need is the ability to predict therapeutic responses for individual patients. Toward this goal, we have established a library of orthotopic glioblastoma (GBM) xenograft models using surgical samples of GBM patients. These patient-specific GBM xenograft tumors recapitulate histopathological properties and maintain genomic characteristics of parental GBMs in situ. Furthermore, in vivo irradiation, chemotherapy, and targeted therapy of these xenograft tumors mimic the treatment response of parental GBMs. We also found that establishment of orthotopic xenograft models portends poor prognosis of GBM patients and identified the gene signatures and pathways signatures associated with the clinical aggressiveness of GBMs. Together, the patient-specific orthotopic GBM xenograft library represent the preclinically and clinically valuable “patient tumor’s phenocopy” that represents molecular and functional heterogeneity of GBMs. aCGH experiments were performed for a human glioblastoma tissue (sample ID: PC-NS08-559) and the matching xenograft tumor tissue using the Agilent Human Whole Genome CGH 244K microarray according to manufacturer's protocol (2-color).

2013-01-18 | E-GEOD-42577 | biostudies-arrayexpress

Comprehensive transcriptomic profiling of glioblastoma patient-derived primary tumor cell lines using bulk RNA-sequencing

Project description:Glioblastoma multiforme (GBM) is a highly aggressive primary brain cancer with significant transcriptomic heterogeneity among patients. Our study aims to contribute to the field of personalized medicine for GBM patients by providing comprehensive transcriptomic profiles of GBM patients (N = 45) who underwent concurrent chemoradiotherapy with temozolomide at Seoul National University Hospital. Additionally, we include transcriptomic profiles of normal brain tissue obtained from GBM patients. This dataset may add depth to existing knowledge by uncovering distinct transcriptomic signatures related to aggressiveness in GBM, and may inform future research on the molecular mechanisms underlying transcriptomic features of GBM and personalized treatment strategies.

2024-04-14 | GSE263588 | GEO

Discovery of PDE7B as a novel effector of GBM growth by computational deconvolution of an in vitro physical coculture system

Project description:Cell-to-cell interactions between tumor cells and their microenvironment are critical determinants of tumor tissue biology and therapeutic responses. Interactions between glioblastoma (GBM) cells and endothelial cells (ECs) establish a purported stem cell niche. We hypothesized that genes that mediate these interactions would be important, particularly as therapeutic targets. Using a novel computational approach to deconvoluting expression data from mixed physical coculture of GBM cells and ECs, we identified upregulation of the cAMP specific phosphodiesterase PDE7B in GBM cells in response to ECs. We further found that elevated PDE7B expression occurs in most GBM cases and has a negative effect on survival. PDE7B overexpression resulted in the expansion of a stem-like cell subpopulation, increased tumor aggressiveness, and increased growth in an intracranial GBM model. This deconvolution algorithm provides a new tool for cancer biology, and these results identify PDE7B as a therapeutic target in GBM. 3 replicates from U87 monocultures, 3 replicates from HBMEC monocultures, 3 replicates from U87-HBMEC cocultures

2014-03-01 | E-GEOD-51253 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data